ImmunityBio Shares 11% Higher on License Application Resubmission for N-803
23 Octubre 2023 - 10:00AM
Noticias Dow Jones
By Dean Seal
Shares of ImmunityBio rose after the company resubmitted a
biological license application for its investigational bladder
cancer treatment N-803.
The stock was up 11% at $1.44 in early trading. Shares have
fallen 71% year-to-date.
The clinical-stage immunotherapy company said Monday that it
resubmitted the application to the U.S. Food and Drug
Administration.
The application is supported by the results of ImmunityBio's
studies in bladder cancer, including a study published last
November.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
October 23, 2023 10:45 ET (14:45 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
ImmunityBio (NASDAQ:IBRX)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
ImmunityBio (NASDAQ:IBRX)
Gráfica de Acción Histórica
De May 2023 a May 2024
